Cardiol Therapeutics Inc. (CRDL)
| Market Cap | 131.66M +50.8% |
| Revenue (ttm) | n/a |
| Net Income | -24.00M |
| EPS | -0.24 |
| Shares Out | 116.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 629,200 |
| Open | 1.160 |
| Previous Close | 1.140 |
| Day's Range | 1.125 - 1.170 |
| 52-Week Range | 0.880 - 2.340 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 8.42 (+632.17%) |
| Est. Earnings | Nov 12, 2026 |
About CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol fo... [Read more]
Analyst Summary
According to 6 analysts, the average rating for CRDL stock is "Strong Buy." The 12-month stock price target is $8.42, which is an increase of 632.17% from the latest price.
News
Tejara Capital Ltd Expands Stake in Cardiol Therapeutics Inc (CRDL) with 1.27 Million Share Purchase
Tejara Capital Ltd Expands Stake in Cardiol Therapeutics Inc (CRDL) with 1.27 Million Share Purchase
Cardiol Therapeutics Slides: Corporate presentation
Cardiol Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Market Implies High Growth ...
Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Market Implies High Growth Despite Unprofitability
Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial
Cardiol Therapeutics (CRDL) announced enrollment progress and plans to expand MAVERIC, the Company’s pivotal Phase III randomized, double-blind, placebo-controlled, multi-center trial evaluating Cardi...
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture suffic...
Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Runway into 2028
Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Runway into 2028
Cardiol Therapeutics Registration statement: Registration filing
Cardiol Therapeutics filed a registration statement on September 16, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics receives over $7M in proceeds from warrant exercise
Cardiol Therapeutics (CRDL) is pleased to announce it has received proceeds of over $7M from the exercise of outstanding common share purchase warrants. The capital raised will extend Cardiol’s cash…
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
Cardiol Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted progress toward completing phase III enrollment for a lead cardiovascular therapy, with pivotal data expected soon and plans to expand into heart failure and mass-market indications. Regulatory alignment and a strong value proposition support broad commercial potential.
Cardiol Therapeutics files $150M preliminary base shelf prospectus
Cardiol Therapeutics (CRDL) announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada, to...
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibro...
Cardiol Therapeutics Registration statement: Registration filing
Cardiol Therapeutics filed a registration statement on September 10, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrot...
Biotech Gainers: SMMT, CELU, BDSX, CRDL And EDSA Advance On Company-Specific Catalysts
(RTTNews) - Today's top gainers in the biotech and healthcare space include Summit Therapeutics, following positive Phase III HARMONi trial data; Celularity, despite a Nasdaq compliance notice; Biodes...
Cardiol Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $11 price target The firm believes the company’s lead candidate, CardiolRx, is “significantly de-risked” in the ongoing...
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics MD&A: Q2 2026
Cardiol Therapeutics filed a regulatory document on August 12, 2026 disclosing important business information.
Cardiol Therapeutics Report: Q2 2026
Cardiol Therapeutics published a report on August 12, 2026 containing material business information for investors and shareholders.
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describi...
Cardiol Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibroti...